Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-06-15
2010-12-28
Helms, Larry R (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S130100, C435S007100
Reexamination Certificate
active
07858756
ABSTRACT:
The invention generally relates to monoclonal antibodies that recognize at least one compound from the group consisting of (+) methamphetamine, (+) amphetamine, and (+) 3,4-methylenedioxymethamphetamine ((+) MDMA). Generally speaking, the monoclonal antibodies do not recognize (−) methamphetamine, (−) amphetamine, or (−) MDMA.
REFERENCES:
patent: 4041076 (1977-08-01), Avenia et al.
patent: 4329281 (1982-05-01), Christenson et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5041076 (1991-08-01), Kantor
patent: 5135863 (1992-08-01), Hu et al.
patent: 5141850 (1992-08-01), Cole et al.
patent: 5160701 (1992-11-01), Brown, III et al.
patent: 5238652 (1993-08-01), Sun et al.
patent: 5328828 (1994-07-01), Hu et al.
patent: 5415994 (1995-05-01), Imrich et al.
patent: 5451504 (1995-09-01), Fitzpatrick et al.
patent: 5492841 (1996-02-01), Craig
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5559041 (1996-09-01), Kang et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5976812 (1999-11-01), Huber et al.
patent: 6087184 (2000-07-01), Magginetti et al.
patent: 6306616 (2001-10-01), Shindelman
patent: 6669937 (2003-12-01), Owens et al.
patent: 7037669 (2006-05-01), Zheng et al.
patent: 7202348 (2007-04-01), Owens et al.
patent: 2003/0119083 (2003-06-01), Owens et al.
patent: 2003/0171435 (2003-09-01), Pouletty et al.
patent: 0239400 (1987-09-01), None
patent: 0343346 (1989-11-01), None
patent: 0574782 (1993-12-01), None
patent: 0375422 (1996-07-01), None
patent: 1331219 (2003-07-01), None
patent: 86/01533 (1986-03-01), None
patent: 92/03163 (1992-05-01), None
patent: 97/49732 (1997-12-01), None
patent: 01/81424 (2001-11-01), None
patent: 2004/050032 (2004-07-01), None
patent: 2007/147122 (2007-12-01), None
International Search Report for PCT/US07/71354 dated Mar. 10, 2008, 10 pages.
Cho, et al., Relevance of Pharmacokinetic Parameters in Animal Models of Methamphetamine Abuse, 2001, pp. 161-166, Synapse, vol. 39.
Sato, et al., Relapse of Paranoid Psychotic State in Methamphetamine Model of Schizophrenia, 1992, pp. 115-122, Schizophrenia Bulletin, vol. 18, No. 1.
Valentine, et al., Antiphencyclidine Monoclonal Antibody Therapy Significantly Changes Phencyclidine Concentrations in Brain and Other Tissues in Rats, 1996, pp. 717-724, JPET, vol. 278, No. 2.
Valentine, et al., Antiphencyclidine Monoclonal Fab Fragments Reverse Phencyclidine-Induced Behavioral Effects and Ataxia in Rats, 1996, pp. 709-716, JPET, vol. 278, No. 2.
International Search Report dated Oct. 10, 2001.
Albertson et al, “Methamphetamine and the Expanding Complications of Amphetamines”, West J. Med, 1999, pp. 214-219 vol. 170, No. 4.
Aoki et al, “Immunoassay For Methamphetamine With A New Antibody”, Forensic Science International, 1990, pp. 245-255, vol. 44.
Byrnes-Blake et al, “Generation of anti-(+)methamphetamine antibodies is not impeded by (+) methamphetamine administration during active immunization of rats”, International Immunopharmacology, 2001, pp. 329-338, vol. 1.
Byrnes-Blake et al, “Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats”, European Journal of Pharmacology, 2003, pp. 119-128, vol. 461.
Byrnes-Blake et al, “Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats”, European Journal of Pharmacology, 2005, pp. 86-94, vol. 521.
Chio et al, “Localization of the epitope in methamphetamine and its antibody use for the detection of methamphetamine and benzphetamine by polarization fluoroimmunoassay”, Journal of Immunoassy, 1995, pp. 263-278, vol. 16(3).
Cody et al, “Detection of D,L-Amphetamine, D,L-Methamphetamine, and Illicit Amphetamine Analogs Using Diagnostic Products Corporation's Amphetamine and Methamphetamine Radioimmunoassay”, Journal of Analytical Toxicology, 1990, pp. 321-324, vol. 14(5).
Colbert et al, “Single-Reagent Polarization Fluoroimmunoassay for Amphetamine in Urine” Clinical Chemistry, 1985, pp. 1193-1195, vol. 31, No. 7.
Cook et al, “Pharmacokinetic of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride”, Drug Metabolism and Dispositions, 1993, pp. 717-723, vol. 21, No. 4.
Danger et al, “Development of murine monoclonal antibodies to methamphetamine and methamphetamine analogues”, Journal of Immunological Methods, 2006, pp. 1-10, vol. 309.
Faraj et al, “Specificity of an Antibody Directed against d-Methamphetamine. Studies with Rigid and Nonrigid Analogs”, Journal of Medicinal Chemistry, 1976, pp. 20-25, vol. 19(1).
Farre et al, “Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics”, Psychopharmacology, 2004, pp. 364-375, vol. 173.
Hardin et al, “Pharmacodynamics of a Monoclonal Antiphencyclidine Fab with Broad Selectivity for Phencyclidine-Like Drugs”, The Journal of Pharmacology and Experimental Therapeutics, 1998, pp. 1113-1122, vol. 285(3).
Kosten et al, “Immunotherapy for the treatment of drug abuse”, Pharmacology and Therapeutics, 2005, pp. 76-85 vol. 108.
Laurenzana et al, “Use of Anti-(+)-Methamphetamine Monoclonal Antibody To Significantly Alter (+)-Methamphetamine and (+)-Amphetamine Disposition in Rats”, Drug Metabolism and Disposition, 2003, pp. 1320-1326, vol. 31(11).
Li et al, “Four-choice drug discrimination in pigeons”, Behavioural Pharmacology, 2001, pp. 621-628, vol. 12.
McMillan et al, “Schedule control of quantal and graded dose-effect curves in a drug-drug-saline discrimination”, Pharmacology, Biochemistry and Behavior, 2001, pp. 395-402, vol. 68.
McMillian et al, “Discrimination of pentobarbital doses and drug mixtures under fixed-ratio and fixed-interval reinforcement schedules”, Behavioural Pharmacology, 2001, pp. 195-208, vol. 12.
McMillian et al, “Pharmacokinetic antagonism of (+)-methamphetamine discrimination by low-affinity monoclonal anti-methamphetamine antibody”, Behavioural Pharmacology, 2002, pp. 465-473, vol. 13.
McMillian et al, “Effects of Murine-Derived Anti-Methamphetamine Monoclonal Antibodies on (+)-Methamphetamine Self-Administration in the Rat”, Journal of Pharmacology and Experimental Therapeutics, 2004, pp. 1248-1255, vol. 309(3).
Nam et al, “Production and Characterization of Monoclonal Antibody That Simultaneously Recognizes Methamphetamine and Its Major Metabolite”, Biological and Pharmaceutical Bulletin, 1993 pp. 490-492, vol. 16(5).
Owens et al, “Antibodies Against Arylcyclohexylamines and Their Similarities in Binding Specificity with the Phencyclidine Receptor”, The Journal of Pharmacology and Experimental Therapeutics, 1998, pp. 472-478 vol. 246(2).
Peterson et al, “Using Hapten Design to Discover Therapeutic Monoclonal Antibodies for Treating Methamphetamine Abuse”, Journal of Pharmocology and Experimental Therapeutics, 2007 pp. 30-39, vol. 322(1).
Peterson et al., “Monoclonal Antibody Form and Function: Manufacturing the Right Antibodies for Treating Drug Abuse”,The AAPS Journal, 2006, pp. E383-E390, vol. 8(2).
Proksch et al. “Anti-Phencyclidine Monoclonal Antibodies Provide Long-Term Reductions in Brain Phencyclidine Concentrations during Chronic Phencyclidine Administration in Rats”, The Journal of Pharmacology and Experimental Therapeutics, 2000, pp. 831-837, vol. 292(3).
Richards et al., “Methamphetamine Abuse and Emergency Department Utilization”, West J Med, 1999, pp. 198-202, vol. 170, No. 4.
Riviere et al. “Spontaneous Locomotor Activity and Pharmacokinetics of Intravenous Methamhetamine and Its Metabolite Amphetamine in the Rat”, The Journal of Pharmacology an
Carroll F. Ivy
Chi Yingni
Gunnell Melinda
Henry Ralph
Owens S. Michael
Helms Larry R
Polsinelli Shughart PC
Sang Hong
The Board of Trustees of the University of Arkansas
LandOfFree
Monoclonal antibodies that selectively recognize... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies that selectively recognize..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies that selectively recognize... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4229727